Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

Rodrigo, M.J. Cardiel, M.J. Fraile, J.M. Mendez-Martinez, S. Martinez-Rincon, T. Subias, M. Polo, V. Ruberte, J. Ramirez, T. Vispe, E. Luna, C. Mayoral, J.A. Garcia-Martin, E. Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

Biomater. sci.

10.1039/d0bm01013h 2020

2020